     |
   |
|
|
Dr. Bratzler has been our Executive Chairman and Chief Executive Officer since March 2008. Previously, Dr. Bratzler was President and Chief Executive Officer of Coley Pharmaceutical Group from 1998 to the time of its sale to Pfizer in January 2008. A co-founder of Sepracor Inc., a research-based pharmaceutical company, in 1984, Dr. Bratzler also co-founded and helped build and finance several Sepracor group companies, including ChiRex, a pharmaceutical outsourcing company, where Dr. Bratzler served as President and Chief Executive Officer from 1996 to 1997. A former faculty member in the department of chemical engineering at Princeton University, Dr. Bratzler received his B.S. degree from the University of Michigan and his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.
Dr. Cole is a General Partner at Flagship Ventures where he focuses on Life Science investments. Prior to Flagship, he served as Program Executive at Vertex Pharmaceuticals, Medical Director at Cytotherapeutics, and as Instructor in Neurology at Harvard Medical School. While at Flagship, he has led investments in Agios Pharmaceuticals, Tetraphase, Quanterix, Concert Pharmaceuticals, Ensemble Discovery, Alvine Pharmaceuticals, Seventh Sense, and CombinatoRx. Dr. Cole co-founded Ensemble Discovery and served as CEO of the company during its initial stages. He currently represents Flagship on the Board of Directors at Agios Pharmaceuticals, Tetraphase, Concert Pharmaceuticals, Ensemble Discovery, AVEO Pharmaceuticals, Quanterix, and CGI Pharmaceuticals, and is an Observer on the Board of Directors of Alvine. Dr. Cole obtained post-graduate training in medicine at the Johns Hopkins Hospital and in neurology at Massachusetts General Hospital. He holds an M.D. from the University of Pennsylvania School of Medicine and received an A.B. magna cum laude with High Distinction in English from Dartmouth College.
Dr. Farokhzad is Associate Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women's Hospital (BWH). He is a co-founder of Selecta Biosciences, a biopharmaceutical company developing immunomodulatory therapeutics and vaccines; and BIND Biosciences, a biopharmaceutical company developing targeted nanoparticle therapeutics. He serves as Director and Vice Chairman on the board of Selecta and as Director on the board of BIND. Dr. Farokhzad's research group is focused on developing novel nanotechnologies for medical applications. He has pioneered the application of micro- and nanotechnology for high throughput development and screening of targeted drug delivery systems for a myriad of clinical applications. Dr. Farokhzad was named among the Nano50 winners of 2007 by Nanotech Briefs which awards the most innovative people and design ideas that will revolutionize nanotechnology. He completed his post-doctoral clinical and research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Dr. Robert Langer. Dr. Farokhzad has authored more than 50 papers and is an inventor of more than 40 pending patents. He received his M.D. and M.A. from Boston University School of Medicine.
Dr. Langer is one of 14 Institute Professors at MIT, and has done pioneering work in the use of biomaterials for tissue engineering and drug delivery, most recently applying nanotechnology for developing novel targeted strategies for cancer therapy. Professor Langer has written over 1000 articles and has over 600 issued or pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 180 pharmaceutical, chemical, biotechnology and medical device companies. He is a founder of over 20 successful companies, including Momenta, Alnylam, Transform Pharmaceuticals, Pervasis and AIR. Professor Langer is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction. In July 2007, he was awarded the National Medal of Science, the highest civilian honor bestowed by the United States. Dr. Langer received his B.S. from Cornell University, and his Sc.D. from the Massachusetts Institute of Technology, both in Chemical Engineering.
Dr. Nashat is a General Partner at Polaris Venture Partners and focuses on investments in the life sciences. Prior to joining Polaris, Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at MIT with a minor in Biology under the guidance of Dr. Robert Langer. During his time at MIT, Amir completed an internship in the London office of Goldman, Sachs & Company, where he worked on interest rate derivative products. Amir currently represents Polaris as a Director of Adnexus Therapeutics, Athenix Corporation, aTyr Pharmaceutials, Avila Therapeutics, Hydra Biosciences, Promedior Pharmaceuticals, Pervasis Therapeutics, where he was founding president, T2 Biosystems and WaveRx, and serves on the Board of the New England Venture Capital Association, on the Advisory Board of the Simmons School of Management Entrepreneurship Initiative, and is a Catalyst for the Deshpande Center for Technological Innovation at MIT. He received his Ph.D. at MIT, and both his M.S. and B.S. in Materials Science and Mechanical Engineering at the University of California, Berkeley.
Aymeric Sallin is the Founder and Managing Director of NanoDimension. Aymeric has led investments in Crocus Technology, Xtellus and Selecta Biosciences and currently represents NanoDimension on the Board of Crocus Technology and Selecta Biosciences. Aymeric has received the "NSTI Fellow Award" for outstanding contributions to the advancement of the international nanotechnology community. Prior to NanoDimension, Aymeric was a strategy consultant at Bain & Company focusing on the high-tech industry. Aymeric received a Masters Degree in Physical Engineering from the Federal Institute of Technology (EPFL) in Lausanne, Switzerland, and currently serves on the Advisory Board of the Physics Department.
Dr. Siber is widely regarded as one of the leading global authorities in vaccines and was previously the Executive Vice President and Chief Scientific Officer of Wyeth Vaccines. While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines including an acellular pertussis vaccine (Acel-Imune), a meningococcal meningitis vaccine (Meningitec), and a pneumococcal vaccine (Prevnar). Prior to joining Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. During this time, Dr. Siber oversaw research and manufacturing of multiple vaccines and immune globulins including Respigam, a human immune globulin against RSV, which was the precursor of Synagis.